{"filing":{"accession_number":"0001193125-26-291114","cik":"0000882361","ticker":"APTOF","company_name":"Aptose Biosciences Inc.","form":"8-K","filing_date":"2026-06-30","report_date":null,"primary_document":"d161768d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/882361/000119312526291114/d161768d8k.htm"},"events":[{"id":15196,"run_id":13563,"accession_number":"0001193125-26-291114","anchor_item_number":"2.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"summary":"Hanmi Pharmaceutical completed its acquisition of all outstanding common shares of Aptose Biosciences not already owned by Hanmi for C$2.41 per share (approximately USD $3.5 million aggregate consideration) pursuant to a statutory plan of arrangement approved by shareholders on March 31, 2026, and consummated on June 30, 2026. The transaction resulted in Aptose becoming a wholly owned subsidiary of Hanmi and delisting from the TSX.","company_name":"Aptose Biosciences Inc.","ticker":"APTOF","filing_date":"2026-06-30","form":"8-K","submitted_at":null,"items":[{"id":12874,"accession_number":"0001193125-26-291114","item_number":"2.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"This Item 2.01 discloses the completion of a statutory plan of arrangement under which Hanmi Pharmaceuticals acquired all outstanding common shares of Aptose Biosciences not already owned by Hanmi for C$2.41 per share (approximately USD $3.5 million aggregate consideration). The transaction was approved by shareholders on March 31, 2026, and consummated on June 30, 2026, resulting in delisting from the TSX. This is a material change of control and acquisition of assets meeting the definition of ma_activity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T11:23:53.358785+00:00","company_name":"","ticker":null,"filing_date":""},{"id":12875,"accession_number":"0001193125-26-291114","item_number":"3.03","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"Item 3.03 discloses the completion of a plan of arrangement whereby Hanmi Pharmaceutical's subsidiary acquired all outstanding common shares of Aptose not already owned by Hanmi, with shareholders receiving C$2.41 per share in cash. The press release confirms this is the \"closing of the plan of arrangement\" and notes the Common Shares will be delisted from the TSX. This is a material acquisition/change of control event (M\u0026A activity) that fundamentally alters the registrant's ownership and public status.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T11:23:53.358785+00:00","company_name":"","ticker":null,"filing_date":""},{"id":12876,"accession_number":"0001193125-26-291114","item_number":"5.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"The filing discloses the completion of an acquisition whereby Hanmi Pharmaceutical (through its subsidiary HS North America Ltd.) acquired all outstanding common shares of Aptose Biosciences that it did not already own, resulting in Aptose becoming a wholly owned subsidiary of the Hanmi Purchasers. This is a material change of control transaction completed under a plan of arrangement, with shareholders receiving C$2.41 per share (28% premium) and the company delisting from the TSX. This is a classic M\u0026A completion event under Item 5.01 and Item 2.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T11:23:53.358785+00:00","company_name":"","ticker":null,"filing_date":""},{"id":12877,"accession_number":"0001193125-26-291114","item_number":"5.02","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The Item 5.02 disclosure centers on the completion of an acquisition by Hanmi Pharmaceutical, wherein all directors resigned as of the Effective Time of the Arrangement. While the Item nominally covers director departures, the substantive event is the consummation of the plan of arrangement (a material acquisition and change of control), evidenced by the press release announcing \"Completion of Acquisition by Hanmi Pharmaceutical\" and the delisting of Aptose's common shares from the TSX. The director resignations are a consequence of the acquisition, not the principal disclosed action.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T11:23:53.358785+00:00","company_name":"","ticker":null,"filing_date":""},{"id":12878,"accession_number":"0001193125-26-291114","item_number":"8.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the completion of a material acquisition whereby HS North America Ltd. (a subsidiary of Hanmi Pharmaceutical) acquired all outstanding common shares of Aptose Biosciences for C$2.41 per share in cash. The arrangement was announced November 19, 2025, approved by shareholders on March 31, 2026, and closed on June 30, 2026. This represents a change of control and is a material M\u0026A event requiring 8-K disclosure under Item 1.01 or 2.01, disclosed here under Item 8.01 as part of the closing announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T11:23:53.358785+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12874,"accession_number":"0001193125-26-291114","item_number":"2.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"This Item 2.01 discloses the completion of a statutory plan of arrangement under which Hanmi Pharmaceuticals acquired all outstanding common shares of Aptose Biosciences not already owned by Hanmi for C$2.41 per share (approximately USD $3.5 million aggregate consideration). The transaction was approved by shareholders on March 31, 2026, and consummated on June 30, 2026, resulting in delisting from the TSX. This is a material change of control and acquisition of assets meeting the definition of ma_activity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T11:23:53.358785+00:00","company_name":"Aptose Biosciences Inc.","ticker":"APTOF","filing_date":"2026-06-30"},{"id":12875,"accession_number":"0001193125-26-291114","item_number":"3.03","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"Item 3.03 discloses the completion of a plan of arrangement whereby Hanmi Pharmaceutical's subsidiary acquired all outstanding common shares of Aptose not already owned by Hanmi, with shareholders receiving C$2.41 per share in cash. The press release confirms this is the \"closing of the plan of arrangement\" and notes the Common Shares will be delisted from the TSX. This is a material acquisition/change of control event (M\u0026A activity) that fundamentally alters the registrant's ownership and public status.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T11:23:53.358785+00:00","company_name":"Aptose Biosciences Inc.","ticker":"APTOF","filing_date":"2026-06-30"},{"id":12876,"accession_number":"0001193125-26-291114","item_number":"5.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"The filing discloses the completion of an acquisition whereby Hanmi Pharmaceutical (through its subsidiary HS North America Ltd.) acquired all outstanding common shares of Aptose Biosciences that it did not already own, resulting in Aptose becoming a wholly owned subsidiary of the Hanmi Purchasers. This is a material change of control transaction completed under a plan of arrangement, with shareholders receiving C$2.41 per share (28% premium) and the company delisting from the TSX. This is a classic M\u0026A completion event under Item 5.01 and Item 2.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T11:23:53.358785+00:00","company_name":"Aptose Biosciences Inc.","ticker":"APTOF","filing_date":"2026-06-30"},{"id":12877,"accession_number":"0001193125-26-291114","item_number":"5.02","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The Item 5.02 disclosure centers on the completion of an acquisition by Hanmi Pharmaceutical, wherein all directors resigned as of the Effective Time of the Arrangement. While the Item nominally covers director departures, the substantive event is the consummation of the plan of arrangement (a material acquisition and change of control), evidenced by the press release announcing \"Completion of Acquisition by Hanmi Pharmaceutical\" and the delisting of Aptose's common shares from the TSX. The director resignations are a consequence of the acquisition, not the principal disclosed action.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T11:23:53.358785+00:00","company_name":"Aptose Biosciences Inc.","ticker":"APTOF","filing_date":"2026-06-30"},{"id":12878,"accession_number":"0001193125-26-291114","item_number":"8.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the completion of a material acquisition whereby HS North America Ltd. (a subsidiary of Hanmi Pharmaceutical) acquired all outstanding common shares of Aptose Biosciences for C$2.41 per share in cash. The arrangement was announced November 19, 2025, approved by shareholders on March 31, 2026, and closed on June 30, 2026. This represents a change of control and is a material M\u0026A event requiring 8-K disclosure under Item 1.01 or 2.01, disclosed here under Item 8.01 as part of the closing announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T11:23:53.358785+00:00","company_name":"Aptose Biosciences Inc.","ticker":"APTOF","filing_date":"2026-06-30"}]}